China SXT Pharmaceuticals Inc (SXTC)vsTeva Pharma Industries Ltd ADR (TEVA)
SXTC
China SXT Pharmaceuticals Inc
$1.36
-3.55%
HEALTHCARE · Cap: $1.20M
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1122007% more annual revenue ($17.26B vs $1.54M). TEVA leads profitability with a 8.2% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 73/100 (B).
SXTC
Hold41
out of 100
Grade: D
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for SXTC.
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 42.6% YoY
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -50.3% — below average capital efficiency
Revenue declined 24.5%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : SXTC
The strongest argument for SXTC centers on Price/Book, EPS Growth.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : SXTC
The primary concerns for SXTC are Market Cap, Profit Margin, Return on Equity.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
SXTC carries more volatility with a beta of 1.74 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (73/100 vs 41/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China SXT Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sale of Traditional Chinese Medicine Tablets (TCMP) in China. The company is headquartered in Taizhou, China.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?